anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Latanoprost was studied in three multicenter, randomized, controlled clinical trials. Patients received 50 mcg/mL latanoprost once daily or 5 mg/mL active-comparator (timolol) twice daily. The patient population studied had a mean age of 65+10 years. Seven percent of patients withdrew before the 6-month endpoint.

Less than 1% of the patients treated with latanoprost required discontinuation of therapy because of intolerance to conjunctival hyperemia.
The present invention provides a composition for relieving, preventing, or treating pain containing a mate extract as an active ingredient. The composition of the present invention has effects of relieving and treating pain that has occurred, and exhibits an effect of preventing pain when being administered to a subject before the pain occurs. The composition of the present invention exhibits a remarkable pain relief effect even through oral administration as well as through intravenous injection, application to skin, or the like. The composition of the present invention having these features is highly applicable to a food. The present invention provides a method for evaluating pain relief, prevention, or treatment efficacy of a sample. The use of the present invention can accurately measure the number of times of occurrence or the duration time of ultrasonic vocalization generated from an experimental animal on pain response and express the measurement results as objective numerical values, so that the present invention is very useful in evaluating pain relief, prevention, or treatment efficacy of the sample, and is capable of minimizing errors of the prior art resulting from individual differences among experimenters and subjective judgments in the measurement of the pain response.
Dysphagia, or abnormal swallowing of foods and/ or liquids, affects people of all ages from the newborn to the elderly. Management of dysphagia is commonly done by the prescription of texture-controlled diets. Ideally, the most appropriate modification of food consistencies should follow from a clear assessment of the swallowing problem. Rheology and swallowing are connected at the diagnosis level. The "gold standard" technique is a videofluoroscopic swallowing study (VFSS). The swallowing process can be visualized using videoradiography by employing either ready-to-use commercial contrast medium or by mixing food with barium sulphate (BaSO4), making it radiopaque. Unfortunately, there is no standardization to perform VFSS. This lack of standardization leads to variability of results as well as their interpretation. In practice, lack of standardization often requires that individual speech pathologist, dieticians and dysphagia food manufacturers determine their own dietary consistencies. Another possibility is the use of encapsulated MRI superparamagnetic contrast agents for oral administration. The main goal of this invention has been to develop new and improved formulations of carriers/vehicles for radio-opaque (barium sulphate) or magnetic contrast agents (superparamagnetic iron oxide) that can be used as ready-to-use/ powder commercial formulations as contrast media for imaging diagnosis (VFSS or MRI) of dysphagia.
PURPOSE: To obtain a medicine compd. containing melatonin to be used for the treatment of benign prostatomegaly(BPH). CONSTITUTION: This medicine compound used for the treatment of male BPH contains a carrier, diluent or adjuvant, and (1) an effective amt. of melatonin for the treatment of BPH, (2) antiandrogen, antiestrogen, growth hormone and/or prostate testosterone reductase suppressant. and/or (3) oxazepam or other melatonin acceptor profile controlling agent. This method features that melatonin is used to produce a medicine for the treatment of male BPH and melatonin is used as a medicine.
NEW MATERIAL:An optically active compound shown by the formula I (R1 is H or CH3; R2 is H or 1-4C alkyl; absolute configuration of 1 position is either R configuration or S configuration) or its acid addition salt. EXAMPLE:(R)-1-Cyclohexyl-2-phenylethylamine. USE:A drug, its intermediate or an analgesic. Since this compound has improved analgesic action is an optical isomer having approximately 100% optical purity, it has more enhanced pharmaceutical action than a racemic modification, has alleviated side effects and is useful as an analgesic for pain of various cancers, gastric ulcer, duodenal ulcer, renal calculus, urinary calculus, arteritis obliterans, etc., or pain after operation or pain caused by a tool for examining the stomach, ureter, urinary bladder, etc. PREPARATION:An optically active 2-phenylethylamine compound shown by the formula II (1' position = 1 position) is subjected to hydrogenolysis in a solvent such as glacial acetic acid, etc., in the presence of a catalyst such as Pd/C, etc., at 5-100 atm. hydrogen pressure at 15-30 deg.C for 12-24hr to give a compound shown by the formula I wherein R2 is H.
An oriental medicine composition having anticancer activity and inhibition effect of side effect of anticancer drug is provided to decrease the toxicity of liver and kidney by administration of anticancer drug and increase anticancer activity. An oriental medicine for suppressing the toxicity of liver and kidney by the administration of anticancer drug comprises 10-15 wt.pt. of Astragali Radix, 5-10 wt.pt. of ginseng, 5-10 wt.pt. of hoelen, 5-10 wt.pt. of Atractylodis Rhizoma alba, 5-10 wt.pt. of Polygonati Rhizoma, 5-10 wt.pt. of Dolichoris Semen, 5-10 wt.pt. of Discoreae Rhizoma and 10-15 wt.pt. of Coicis Semen. The amount of administration of the oriental medicine composition is 5-20 mg/kg. The anticancer drug is cisplatin.
The present invention relates to a preparation method for a liver protecting and drunkenness dispelling liquid medicine. The liquid medicine is prepared by carrying out the working procedures of decoction, filtering, concentration and impurity elimination on dendrobium as the raw material. In addition, during the preparation, flower of kudzuvine, wild jujube kernel, etc. as supplementary materials as well as seasonings, suspension assistants, preservative agents, refrigerants, etc. as auxiliary agents can also be added in order to obtain greater effect. The liquid medicine is translucent and has the action of protecting liver, eliminating upset after drinking, promoting appetite, preventing sunstroke, promoting the secretion of saliva and refreshing the mind. The liquid medicine can protect the health of alcohol users effectively.
Rivaroxaban 15 mg po bid x 3 weeks, followed by rivaroxaban 20 mg po daily x 9 weeks. Then up to discretion of investigator to decide regarding further anticoagulation as study length is limited to 12 weeks.
Everolimus (RAD001) has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation and has obtained marketing authorization (Certican®) for prophylaxis of rejection in renal and cardiac transplantation in a number of countries, including the majority of the European Union. Everolimus has been in development for patients with various malignancies since 2002. Everolimus 2.5mg, 5mg and 10mg tablets were approved under the trade name Afinitor® for patients with advanced renal cell carcinoma (RCC) after failure of treatment with Sutent® (sunitinib) or Nexavar® (sorafenib) in the US, EU and several other countries and is undergoing registration in other regions worldwide. Afinitor® was also recently approved for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) who require therapeutic intervention but are not candidates for curative surgical resection. Everolimus is being investigated as an anticancer agent based on its potential to act: 1. Directly on the tumor cells by inhibiting tumor cell growth and proliferation; and 2. Indirectly by inhibiting angiogenesis leading to reduced tumor vascularity.

For pediatric cancer patients, safety of RAD001 has been established in a phase 1 trial and the recommended phase II dose is 5 mg/m2 once daily. This existing pediatric data allows for inclusion of children in this phase 2 trial, which is an important consideration since some NF2 patients with the most aggressive clinical course present at school age.

RAD001 was recently approved by the Food and Drug Administration (FDA) for the treatment of children and adults with subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS). Although surgical resection is effective at tumor reduction, serious complications may follow a radical resection, such as permanent deafness and facial nerve damage. Most importantly, the tumors often recur after surgery. Radiation therapy (RT) has been proposed as an alternative. However, its safety and efficacy in the NF2 population has not been established. A medical therapy option is desperately needed. This study is a single-center, 2-stage, phase II open-label study. All subjects will get RAD001 taken continuously until disease progression or unacceptable toxicity. The primary objective of this study is to look at the objective response rate to RAD001 in patients with NF2-related tumors including cranial nerve schwannomas, meningiomas and ependymomas. Participation will consist of screening/baseline visit(s), Day 1, Weeks 1, 2, and 4; and up to 12 cycles and will include standard of care procedures such as medical history, vital signs, physical examinations, ECGs, MRIs, audiograms, and laboratory tests. Novartis will provide the RAD001 free of charge to eligible study subjects. The primary efficacy response for study purposes will be a greater than or equal to 15% reduction in tumor volume in any of the target tumors (partial response). Complete disappearance of any of the target tumors will constitute a complete response (CR).
The present invention addresses the problem of providing a new means for promoting the growth of Faecalibacterium spp. The solution to this problem is a composition that contains Acidipropionibacterium ( Acidipropionibacterium ) spp. or a treated product thereof and that satisfies at least one requirement selected from (A)-(D) below:　(A) The composition promotes the growth of Faecalibacterium ( Faecalibacterium ) spp. (B) The composition improves a symptom or condition in which Faecalibacterium spp. is involved. (C) The composition is a substitute for sugars that promote the growth of Faecalibacterium spp. (D) The total content of sugars that promote the growth of Faecalibacterium spp. in the composition is 15 mass% or less.
4D flow MRI is an emerging imaging modality that maps voxel-wise blood flow information as velocity vector fields that is acquired in 7-dimensional image volumes (3 spatial dimensions + 3 velocity directions + time). Blood flow in the cardiovascular system is often complex and composite involving multiple flow dynamics and patterns (e.g., vortex flow, jets, stagnating flow) that occur and interact simultaneously. The spectrum of such complex flow dynamics is embedded in the velocity vector field dynamics derived from 4D Flow MRI. However, current flow metrics cannot fully measure high-dimensional vector-field data and embedded complex composite flow data. Instead, these methods need to break down the vector-field data into secondary scalar fields of individual flow components using fluid dynamics operators. These methods are gradient-based and sensitive to data uncertainties, and only focus on individual flow components of the overall composite flow, therefore potentially underestimating the severity of overall flow changes associated with cardiovascular diseases. To address these limitations, in MICCAI 2021, we introduced a novel comprehensive stochastic 4D Flow vector-field signature technique that works directly on the entire spatiotemporal velocity vector field. This technique uses efficient stochastic gradient-free interrogation of multi-million flow vector-pairs per patient to derive the patient's unique flow profile of the complex composite flow alterations and in real-time processing. The signature technique's probabilistic gradient-free formulation should allow for highly robust quantification despite inherent errors in 4D flow MRI acquisitions. Here, we extend the application of the 4D flow vector-field signature technique to the left atrium to analyze complex composite flow changes in patients with atrial fibrillation. In 128 subjects, we performed extensive sensitivity testing and determined that the vector-field signature technique is highly robust to typical sources of data uncertainties in 4D flow MRI: degradation in spatiotemporal resolution, added Gaussian noise, and segmentation errors. We demonstrate the excellent generalizability of the stochastic convergence from the aorta to the left atrium and between different 4D Flow MRI acquisition protocols. We compare the robustness of our technique to existing advanced flow quantification metrics of kinetic energy, vorticity, and energy loss demonstrating a superior performance of up-to 14-fold. Our results show the potential diagnostic and clinical utility of our signature technique in identifying distinctly altered composite flow signatures in atrial fibrillation patients independent of existing flow metrics.
This invention relates to a natural killer cell line termed NK-92 and to NK-92 cell lines that have been modified by transfection with a vector to confer advantageous properties. Additionally, the invention provides an NK-92 cell, an NK-92 cell modified by transfection with a vector conferring advantageous properties, which is unable to proliferate and which preserves the effective cytotoxic activity. The invention provides a modified NK-92 cell line that is transfected with a vector encoding a cytokine that promotes the growth of NK-92 cells. In a significant embodiment, the cytokine is interleukin 2. The invention additionally provides a modified NK-92 cell line that is transfected with a vector that expresses a thymidine kinase gene. The invention further provides a modified NK-92 cell line that is transfected with a vector that expresses a β2 microglobulin that has lost the ability to bind to T-cell receptors.
The COVID-19 pandemic becomes a global challenge. Beneficial to being an island country and having appropriate policies, there were only few imported cases in Taiwan. However, many locally acquired cases came out in the mid of this May. The hospital policy about containing infection changed accordingly.

A real-time communication platform for the health care workers was designed and embedded in the hospital information system of the emergency department in 2018. The functions included sending messages to certain staff, pop-up reminders, and tracking messages. This study aims to evaluate the use of the communication platform during the COVID pandemic.
The optimal time of dialysis initiation is still controversial. Estimated glomerular filtration rate (eGFR) which is now widely used as the assessment of timing of dialysis is lack of specificity. Some clinical factors such as heart failure, volume overload, malnutrition also determine the dialysis time. But these subjective judgements do not have a standard. So there is no quantitative assessment of timing of dialysis initiation. The research team developed a novel equation named DIFE (Dialysis Initiation based on Fuzzy mathematics Equation) with data from a retrospective multicenter cohort by fuzzy mathematical methods to combine these clinical factors and lab indexes. The DIFE was confirmed to be more accurate and convenient to use in clinical practice than eGFR only at the assessment of dialysis initiation time in the internal validation. For further validation of the DIFE, the team will conduct a multicenter randomized controlled trial. Patients who need hemodialysis will be randomized to optimal start dailysis group or late start dailysis group by the assessment of the DIFE. Based on the comparison of the two groups, this trial will provide evidence for the optimal timing of dialysis initiation in patients with end-stage renal disease by the DIFE.
PURPOSE:To obtain saponin of high purity without containing isoflavones on an industrial scale, by adding water to an extract concentrate of soybean embryo buds with a lower alcohol, adsorbing the extract on an adsorbent, eluting the adsorbed extract stepwise with a hydrophilic organic solvent and purifying the eluate by gel filtration, etc. CONSTITUTION:Soybean embryo buds are extracted with a lower alcohol and concentrated, and water is then added thereto. The resultant extract is then adsorbed on an adsorbent, e.g. HP-20, HP-40, etc., and isoflavones are mostly washed and removed with 10-40% methanol, ethanol, acetone, etc. The adsorbed extract is subsequently eluted with 70-80% methanol, ethanol, etc., to give an eluate, which is then purified by gel filtration and partition chromatography to afford the aimed saponin containing no isoflavones. Thereby, the isoflavones giving side effect to the human body are removed from the soybean embryo buds with a higher saponin content than soybean flour and the aimed saponin of high purity can be obtained in large amounts industrially.
Patients who have undergone colonic resection for colorectal cancer in the last 10 years. Patient reported outcome measures collected at 3-monthly intervals.
The experimental group participants (approximately 20 participants) will receive, a standard graduated return-to-run program, a 4-week lower-extremity exercise program, and an activity log to track exercise progress. Participants will be instructed to follow-up with their research physical therapist once a week for the first 4 weeks and then every other week until the run progression is completed. During follow-ups experimental group participants will receive gait retraining cues to transition to a NRFS running pattern.
Clinical experience with fluoxetine in patients with concomitant systemic illness is limited. Caution is advisable in using fluoxetine in patients with diseases or conditions that could affect metabolism or hemodynamic responses. 

Cardiovascular — Fluoxetine has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were systematically excluded from clinical studies during the product’s premarket testing. However, the electrocardiograms of 312 patients who received fluoxetine in double-blind trials were retrospectively evaluated; no conduction abnormalities that resulted in heart block were observed. The mean heart rate was reduced by approximately 3 beats/min.
INTRODUCTION: Over a fifth of pregnant women are living with multiple long-term health conditions, which is associated with increased risks of adverse outcomes for mothers and infants. While there are many examples of research exploring individuals' experiences and care pathways for pregnancy with a single health condition, evidence relating to multiple health conditions is limited. This study aimed to explore experiences and care of women with multiple long-term health conditions around the time of pregnancy.
METHODS: Semistructured interviews were conducted between March 2022 and May 2023 with women with multiple long-term health conditions who were at least 28 weeks pregnant or had had a baby in the last 2 years, and healthcare professionals with experience of caring for these women. Participants were recruited from across the United Kingdom. Data were analysed using thematic analysis.
RESULTS: Fifty-seven women and 51 healthcare professionals participated. Five themes were identified. Women with long-term health conditions and professionals recognised that it takes a team to avoid inconsistent care and communication, for example, medication management. Often, women were required to take a care navigation role to link up their healthcare providers. Women described mixed experiences regarding care for their multiple identities and the whole person. Postnatally, women and professionals recognised a downgrade in care, particularly for women's long-term health conditions. Some professionals detailed the importance of engaging with women's knowledge, and recognising their own professional boundaries of expertise. Many participants described difficulties in providing informational continuity and subsequent impacts on care. Specifically, the setup of care systems made it difficult for everyone to access necessary information, especially when care involved multiple sites.
CONCLUSION: Pregnant women with long-term health conditions can experience a substantial burden of responsibility to maintain communication with their care team, often feeling vulnerable, patronised, and let down by a lack of acknowledgement of their expertise. These results will be used to inform the content of coproduction workshops aimed at developing a list of care recommendations for affected women. It will also inform future interventional studies aimed at improving outcomes for these women and their babies.
PATIENT OR PUBLIC CONTRIBUTION: Our Patient and Public Involvement group were involved in the design of the study and the analysis and interpretation of the data, and a public study investigator was part of the author group.
Diclofenac sodium is a benzeneacetic acid derivative, designated chemically as 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt. The structural formula is:

Diclofenac sodium is a faintly yellowish white to light beige, virtually odorless, slightly hygroscopic crystalline powder. It is freely soluble in methanol, soluble in ethanol, sparingly soluble in water and practically insoluble in chloroform and in dilute acid. The n-octanol/water partition coefficient is 13.4 at pH 7.4 and 1545 at pH 5.2. Diclofenac sodium has a dissociation constant (pKa) of 4.0 ± 0.2 at 25°C in water.

Each enteric-coated tablet for oral administration contains 25 mg, 50 mg, or 75 mg of diclofenac sodium. In addition, each tablet contains the following inactive ingredients. Inactive ingredients: Black iron oxide, croscarmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose (monohydrate), magnesium stearate, methacrylic acid copolymer, microcrystalline cellulose, polyethylene glycol, povidone, red iron oxide, and titanium dioxide. The 25 mg also contains: D&C Yellow #10 Aluminum Lake and pharmaceutical glaze shellac. The 50 mg also contains: Pharmaceutical glaze shellac and yellow iron oxide. The 75 mg also contains: carnauba wax, glycerol monostearate, shellac, and yellow iron oxide.
PURPOSE: To obtain new tetrahydroindazole, tetrahydrocyclopentapyrazole and hexahydrocycloheptapyrazole compounds effective for the treatment or prevention of hypercholesterolemia, etc.  
     CONSTITUTION: A compd. of the formula I [wherein R 2  is H, alkyl, (substd.) aryl or (substd.) aralkyl, etc.; R 3  is H or together with R 2  may form a benzo or naphtho ring; (n) is 0-3] is treated with a base at -78 to 0°C in THF, and acylated with methyl dimethoxyacetate to form diketone of the formula II. The diketone is then treated with substd. hydrazine in a solvent and thereafter hydrolyzed with 1N HCl to form radioisomeric aldehydes of the formula III that are separable. Then, they are allowed to react with methyl 6- dimethoxyphosphinyl-5oxocaproate of the formula IV (wherein t-Bu is t-butyl) and thereafter reduced, to obtain an objective compd. of the formula V [wherein R 1  is H, alkyl or (substd.) aryl; Y is alkyl, etc.; Z is the formula VI (in which R 4  is H or alkyl, etc.) and others]. 
     COPYRIGHT: (C)1993,JPO